Research and development of irinotecan derivative (SN38)-peptide conjugate against Sortilin-positive colorectal cancers

The major aim of this research project is to accelerate the development of the SORT1+ oncology platform. This
novel platform is based on a new proprietary peptide targeting Sortilin, a key scavenging receptor. Sortilin has
been reported to play a role in cell survival and in the progression of human cancers. For instance, Sortilin
expression has been associated with the aggressiveness of breast cancers and was observed in other highly
metastatic types of cancers such as colorectal cancer (CRC), melanoma and lung cancers. Data that will be
generated from this intern will further validate the anti-CRC properties of our irinotecan/SN38-peptide conjugate
in CRC cancer animal models and improve the value of SORT1+ technology. The achievement of milestones in
this project will create significant value for the partner organization and validate SORT1+ technology as a platform.
This will be a key and significant inflexing point for the value of the company that will facilitate the creation of new
partnerships and the development of new research projects.

Faculty Supervisor:

Borhane Annabi

Student:

Partner:

Theratechnologies

Discipline:

Life Sciences

Sector:

Manufacturing; Professional, scientific and technical services

University:

Université du Québec à Montréal

Program: